Press Release

David Brennan Elected PhRMA Board Chairman

PhRMA April 3, 2009

Washington, D.C. (April 3, 2009) — David Brennan, Chief Executive Officer, AstraZeneca, was elected board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting. Also elected were Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler as chairman-elect of the PhRMA Board of Directors and David Y. Norton, Company Group Chairman, Worldwide Commercial and Operations for the Johnson & Johnson Pharmaceuticals Group, as board treasurer.

Mr. Brennan succeeds Richard T. Clark, Chief Executive Officer and President of Merck, as PhRMA’s chairman.

“It has been a privilege to work with Dick this past year,” said PhRMA President and Chief Executive Officer Billy Tauzin. “Under his unfaltering leadership and guidance, our industry has strengthened its commitment to responsible, informative relationships with health care professionals and consumers, we have maintained our collective commitment to world-leading medical innovation and we have worked together to improve patient access to life-changing medicines.”

“The PhRMA member companies accomplished much this past year. We strengthened our marketing code, tightened our DTC advertising principles and voiced strong support of transparency of company interactions with physicians,” said Clark. “I am also proud of PhRMA’s commitment in support of health care reform, including expanding coverage to all Americans. In this time of economic turmoil, the last thing American families should have to worry about is their health care coverage. No one should have to go without the medicines and vaccines they need.”

Mr. Brennan was named chief executive officer of AstraZeneca in January 2006. From 2001 through 2005 he was president and chief executive officer of AstraZeneca LP, the company’s North America subsidiary. In 2005, Mr. Brennan was appointed executive board director of AstraZeneca, with responsibility for all North American operations.

Mr. Brennan, who began his career in 1975 as a sales representative at Merck, joined AstraMerck in 1992 to help build the joint venture into a multibillion dollar business in the U.S. Prior to the AstraZeneca merger he oversaw business planning and development at Astra Pharmaceuticals, and was appointed senior vice president of commercial operations at AstraZeneca Pharmaceuticals LP in 1999.

“The pharmaceutical industry is uniquely poised to be both a source of innovative medicines and a trusted member of the health care community. American pharmaceutical researchers and manufacturers can play a critical role in advancing health solutions that build on the strengths of the U.S. healthcare system and address its weaknesses,” said Brennan as he assumed the chairmanship of PhRMA. “I look forward to working with my industry colleagues, policymakers, health advocacy organizations and new, nontraditional partners to promote policies that expand access to affordable health coverage, address the burden of chronic disease and close the gaps in health care quality while fostering continued innovation.”

“We have a rare opportunity this year to strengthen our health care system in America,” said Tauzin. “We remain committed to work side by side with the Administration, Congress and all stakeholders who are striving to ensure that all Americans have access to affordable, high quality health care coverage. And we will continue our efforts to preserve and fortify policies that foster innovation in our country – policies that have enabled the U.S. to lead the world in the discovery and development of new medicines for patients. I look forward to tackling these challenges with David and the rest of the PhRMA board.”

Mr. Kindler was named Pfizer’s chief executive officer in July 2006 and has served as chairman of the company’s board since December 2006. He joined Pfizer in 2002 as executive vice president and general counsel, with responsibility for Pfizer’s legal division. He was named vice chairman in 2005, joining the company’s four-person executive committee and assuming responsibility for Pfizer’s corporate affairs division.

Prior to joining the pharmaceutical industry, Mr. Kindler served as vice president of litigation and legal policy at General Electric. He also served as executive vice president and general counsel at McDonald’s Corporation before moving into line management at McDonald’s Corporation as president of partner brands. A graduate of Harvard Law School, Mr. Kindler began his legal career as an attorney at the Federal Communications Commission. He later served as law clerk to U.S. Supreme Court Justice William J. Brennan, Jr.

“For the first time in decades, there is broad agreement across the political spectrum and the private sector on need for health reform and on the urgency to act. Today, we see broad support for an approach that includes both the private and the public sectors to improve health care coverage, its quality and affordability,” said Kindler. “As we go about reforming health care, I look forward to working with other PhRMA members to ensure we maintain support for the kind of innovation that will lead to new break-through medical treatments.”

Mr. Norton has been company group chairman, worldwide commercial and operations for the Johnson & Johnson Pharmaceuticals Group since 2006. Prior to assuming his current role, he was named company group chairman for the pharmaceutical businesses in North America and Canada in 2001, and then company group chairman for Europe, Middle East, and Africa.

During his 30-year career at Johnson & Johnson, Mr. Norton has held a wide range of management positions of increasing responsibility in Europe, Australia, New Zealand and the U.S. He began his J&J career in 1979 as a product manager for the company’s affiliate, Janssen Pharmaceutica, in Australia.

“As health care reform discussions move forward, it’s important that our industry continue to deliver meaningful innovation and access to patients who depend on us,” said Norton. “I look forward to working with the PhRMA Board and our member companies to help ensure our health care system remains centered on the individual, offers access to health care coverage for all, and provides people with the means to remain healthy, get early diagnoses, and receive quality care and treatment when needed."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit: